Aspirin and ticlopidine are used to prevent arterial thrombosis. In some clinical settings ticlopidine is administered with aspirin for improving antithrombotic effect. We administered aspirin (100 mg/day), ticlopidine (500mg/day), or ticlopidine and aspirin for 7 days to healthy volunteers. Platelet aggregation and ATP release induced by sodium arachidonate, ADP, or a combination of both were measured. Sodium arachidonate (0.25 mmol/L), which produces no platelet aggregation, combined with adenosine diphosphate (1 &mu;mol/L), which produced a reversible platelet aggregation of 20% after ticlopidine, resulted in a synergistic platelet aggregation response in normal (74.6 & p l u s m n ; 9.2%) and in ticlopidine platelet-rich plasma
(59.1% & p l u s m n ; 14.9%, p < 0.0001). Synergism after sodium arachidonate (0.75 mmol/L) plus adenosine diphosphate (4 &mu;mol/L) fell from 75.8% & p l u s m n ; 11.0% and 59.1% &plusmn; 15.6% after ticlopidine or aspirin, respectively, to 14.8% & p l u s m n ; 18.0% (p < 0.0001) after ticlopidine plus aspirin. Aspirin and ticlopidine alone did not inhibit adenosine triphosphate release as thoroughly as did aspirin plus ticlopidine. Aspirin or ticlopidine does not adequately prevent platelet activity as ticlopidine plus aspirin do. Addition of aspirin to treatment with ticlopidine improves their antiplatelet activity and better results could be obtained in arterial thrombotic prevention strategies. Key Words: Aspirin&mdash; Ticlopidine&mdash;Antiplatelet treatment&mdash;Antithrombotic therapy.
The role of aspirin (acetylsalicylic acid, ASA) in reducing the risk of myocardial infarction or ischemic cerebrovascular disease in patients with a history of arterial compromise is well established (1) . Aspirin induces a long lasting functional defect in platelet via a permanent inactivation of the enzyme cyclooxygenase (prostaglandin G and H synthase) that catalyzes the conversion of arachidonic acid to prostaglandin H2 (2) . The usual dose of ASA ranges between 80 and 500 mg/day. However, ASA alone is an insufficient antithrombotic therapy in some clinical circumstances. Ticlopidine and clopidogrel, two thienopyridines that inhibit the binding of adenosine diphosphate (ADP) to its platelet receptor (3), have been shown to be slightly superior to ASA as an antithrombotic agent (4, 5) . Ticlopidine used together with ASA has given better results than ASA alone in preventing reocclusion after stent implantation (6, 7) and in inhibiting the activation of coagulation mechanism in patients undergoing coronary angioplasty (8) .
Therefore, we investigated whether ASA has addi-tional effects by comparing the platelet response to sodium arachidonate and/or ADP as aggregation inducers, using a pair of agonists (9, 10) instead of the usual sodium arachidonate or ADP alone, in the platelet-rich plasma of healthy volunteers after they had received a short course of ASA, ticlopidine, or both.
MATERIALS AND METHODS

Subjects
Healthy volunteers, men and women ages 24 to 64, without a history of thromboembolic or hemorrhagic diseases, dyslipemia, or renal, hepatic, or malignant diseases were forbidden to take any drugs from 10 days before the study period or throughout the study period except for the drug under investigation. Written informed consent was obtained before entry into the study. One group of nine volunteers ingested a single dose (200 mg) of ASA on day 1, then 100 mg/day for 7 days. Blood samples were collected just before and 12 hours after the last dose. After a 14-day washout, the nine volunteers ingested 250 mg ticlopidine twice daily for 7 days and blood samples were drawn at the times indicated above. Afterwards, the same volunteers ingested 250 mg ticlopidine twice daily and 100 mg/day ASA for 7 days, and blood samples were drawn 12 hours after the last dose.
The ASA tablets (100 mg) were from Bayer Laboratories (Buenos Aires, Argentina). Ticlopidine was supplied by Sanofi (Buenos Aires, Argentina). Plastic syringes, tubes, and pipettes were used for all platelet functional tests. Blood was drawn from the antecubital vein without stasis and mixed with 0.1-mol/L sodium citrate ( 1:10 v/v). Platelet-rich plasma (PRP) was obtained by centrifugation at 900g for 10 minutes and platelet-poor plasma (PPP) by centrifuging PRP at 8,200g for 2 minutes at room temperature. Platelet-poor plasma was adjusted to a platelet count of 300,000/mL with autologous PPP. Contamination of PRP with other blood cells was minimized by repeated centrifugation.
Platelet aggregation and adenosine triphosphate (ATP) release in PRP were measured photometrically in a double-channel Lumi-Aggregometer (Chrono-log Corp, Havertown, PA, U.S.A.). The light transmittance was set at 10% for PRP and 90% for PPP. Platelet-rich plasma (450 pill) was added to 40 pull of luciferin-luciferase reagent (Chrono-lume [Chrono-log Corp.]) in a cuvette. Aggregating agent (1-10 p,L) was then added to the mixture in an aggregometer well at 37°C with constant stirring (1,000 rpm). The aggregating agents used were arachidonic acid, sodium salt, and ADP (Sigma Chemical Co., St. Louis, MO, U.S.A.) and dissolved in NaCl (0.15mol/L).
Aggregation was measured as the maximal percentage transmittance 1 minute and 4 minutes after addition of the agonist. Adenosine triphosphate release was simultaneously measured after calibrating the luminescence curves against an ATP standard (Chrono-log Corp.).
The degree of synergism obtained with pairs of agonists was studied by comparing the sum of aggregation values obtained using each agonist separately with the aggregation value obtained using two agonists together. The sum of aggregation (percent light transmittance) values provides only an approximation of additive effect, since the relationship between platelet aggregation and percent transmittance is not a linear function.
Statistical analysis
Changes were assessed by a nonparametric analysis of variance (ANOVA) for repeated measures (Friedman test). Differences between measures were assessed post hoc Student-Newman-Keuls test by ranks. All data are expressed as mean ± SD. A value of p < 0.05 was considered significant.
RESULTS
Ticlopidine and platelet aggregation
Sodium arachidonate alone in a final concentration 0.25 mmol/L produced no aggregation (<2%) in the PRP obtained from normal volunteers at baseline or in PRP from the same subjects after they had taken ticlopidine 500 mg/day for 7 days or in PRP from subjects after ASA 100 mg/day for 7 days (Table 1 , line 1). However, so-dium arachidonate at 0.75 mmol/L did produce aggregation around 40% at I minute in baseline PRP, unaffected or even slightly enhanced in ticlopidine PRP, but completely prevented in ASA and ticlopidine plus ASA PRPs (Table 1 , line 2). The same results were obtained 4 minutes after addition of the agonist.
With ADP at 1 pLmol/L, the modest aggregation induced (value just under 20% after 1 minute) was unchanged by ticlopidine, ASA, or ticlopidine plus ASA treatment (Table 1, line 3). After 4 minutes, the value for PRP at baseline was the same, but at this time point it was much lower after ticlopidine or ticlopidine plus ASA treatment, and unaffected by ASA alone. With ADP at the higher concentration of 4 pLmol/L, only the ticlopidine plus ASA value was different from the 1-minute baseline value; after 4 minutes the aggregation (57.2%) was equally lower than baseline in ticlopidine and ASA subjects (32.4% and 33.1 %, respectively) and much lower (6.1 %) when the two drugs had been taken simultaneously.
Sodium arachidonate (0.25 mmol/L) plus ADP ( [tmol/L) resulted in a synergistic aggregation response in baseline PRP, 50.5% and 74.6% of maximal transmittance at 1 and 4 minutes, respectively, and in ticlopidine PRP, 41.9% and 59.1 % at 1 and 4 minutes, respectively (Table 1, line 7). The synergistic effect of sodium arachidonate (0.75 mmol/L) plus ADP (4 pLmol/L) in baseline PRP (73.3%) was similar to those obtained in ticlopidine PRP (75.8%, p = NS) or in ASA-PRP (59.1%, p = NS) but fell in ticlopidine plus ASA PRP (14.8%,p < 0.0001) (Table 1, line 6). Table 2 shows the inhibitory effect of ticlopidine and ASA on the release of ATP during platelet aggregation in the various PRP preparations.
Antiplatelet drugs and ATP release
Aspirin resulted in a statistical significant decrease of ATP release induced by sodium arachidonate (0.75mmol/L), ADP (4)JLmol/L or 1 p,mol/L), from 2.74, 1.8, and 1.08 to 0% (p < 0.0001 for all). The decrease was less evident but still statistically significant using arachidonic acid plus ADP. Ticlopidine was less efficient than ASA for preventing ATP release in PRP stimulated by sodium arachidonate. Aspirin plus ticlopidine in vivo almost completely prevented ATP release after platelet activation induced by single or combined agonists (Table 2 ). Figure 1 shows the effect of different agonists and their synergistic activity measured after 1 and 4 minutes and the inhibitory effect of agents used singly or in combination.
DISCUSSION
Antiplatelet treatment must be efficient enough to prevent the platelet activation that can result from the joint TABLE 1. Effect of ticlopidine (Tic-PRP), aspirin (ASA-PRP), and combination of these (Tic + ASA PRP) on platelet aggregation Baseline, normal volunteers stabilized before dosing; Tic, same volunteers after 500 mg/day ticlopidine for 7 days; Tic + ASA, same volunteers after 500 mg/day ticlopidine plus 100 mg/aspirin for 7 days; ASA, same volunteers 100 mg/day aspirin for 7 days, after washout period; 0.25 AA = sodium arachidonate, final concentration 0.25 mmol/L; 0.75 AA = sodium arachidonate, final concentration 0.75 mmol/L; 1 ADP = ADP, I p,mol/L. 4 ADP = ADP, 4 p,mol/L. *p < 0.0001, tp = 0.01, tp = 0.003, §p = 0.005, for Tic versus Tic + ASA; 9[p0.01 < 0.0001 for ASA or Tic versus baseline. activity of several agonists that accumulate at the site of endothelial cell lesions (11) . Some platelet-derived products are also mitogens that induce endothelial and smooth muscle proliferation (12) resulting in arterial stenosis. Aspirin is widely used to prevent thrombotic complications of arterial injury, but under some experiment conditions (9, 10) has been found to be incapable of inhibiting platelet aggregation when a pair of agonists was used to active the platelets in PRP. Thrombin generated at the lesion can also induce platelet activation, and this activity is not affected by ASA (13) . Maalej and Folts (14) also showed, in a canine model with coronary artery stenosis, that ASA did not prevent the reduction in cyclic flow. As several potential agonists are released when endothelium is damaged, not only from platelet but also from endothelial cells (erythrocytes and leukocytes), it may be supposed that the inhibitory effect of ASA may also be overcome in vivo.
Santos et al. (15) found that the synergistic activity between red blood cells and platelets in promoting thrombosis formation was not prevented by low-dose ASA but only by 500 mg/day. The implication being that patients taking ASA may not be fully protected from arterial thrombosis (16) .
The present study has confirmed our previous finding (9) that ASA does not prevent aggregation when this is induced by the combined agonists sodium arachidonate and ADP, an activity independent of thromboxane since under this condition thromboxane generation was very low (9) . In addition, it establishes that ticlopidine is similarly ineffective, but that the combination of ASA with ticlopidine significantly reduces platelet aggregation and platelet release of ATP in response to sodium arachidonate plus ADP.
The results are compatible with the study by Lecompte et al. (17) , in which platelet aggregation was inhibited by ASA (40 mg/day) together with ticlopidine. Recently, the study by Rupprecht et al. (18) also demonstrated synergistic platelet inhibitory effect of ticlopidine plus ASA in platelet aggregation and P-selectin expression.
In the present study a certain degree of synergism was also observed in ATP release after ASA, or after ticlopidine therapy using paired agonists. Responses such as these have been noted previously for ASA (19) ; they may be mediated through membrane receptor modulation.
It is difficult to determine if the remaining platelet activity is potentially thrombogenic. Statistically signifi- FIG. 1. Synergism between arachidonic acid and adenosine diphosphate (ADP) was observed for adenosine triphosphate (ATP) release at baseline and after aspirin or ticlopidine ingestion. Ticlopidine was less efficient than aspirin in preventing ATP release. Aspirin plus ticlopidine in vivo produced a virtually complete inhibition of ATP release. cant differences noted in the text or tables, indicating partial inhibition of platelet aggregation, do not necessarily guarantee beneficial biological effect in antithrombotic therapy. The combination of ticlopidine and ASA greatly enhanced the effect on platelet aggregation (Table 1 ) and virtually abolished ATP release.
Clinical implications
These results imply that ASA should be included in any antiplatelet strategy that uses ticlopidine (and maybe clopidogrel), a strategy that could be mandatory in acute situations. Indeed, Gregorini et al. (8) and Byme et al. (20) , showed increased platelet activation and thromboxane A2 formation in patients undergoing coronary angioplasty. Furthermore, a long-term trial for the prevention of thrombotic events in coronary diseases, combining ticlopidine (or clopidogrel) and ASA could be justified, since, according to Catella-Lawson and FitzGerald (21) the superiority of clopidogrel over ASA is marginal.
